(CercleFinance.com) – Genfit climbs by more than 7% on the back of favorable comments from Oddo BHF which reaffirms its ‘outperformance’ opinion and raises its price target from 8.8 to 9.3 euros on the company’s stock biopharmaceutical.
The design office is reassuring the day after good phase III study results unveiled the day before by the American company Cymabay for its seladelpar, the main competitor to Ipsen/Genfit’s elafibranor in primary biliary cholangitis.
‘In terms of time to market, elafibranor remains mechanically ahead by a few months’, judges the analyst, who does not modify his market hypotheses with a launch of this product in 2024 for peak sales of 411 million euro in 2030.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
